Good results for Merck's Sperm Quality Analyser (SQA):
This article was originally published in Clinica
German company Merck KGaA's Sperm Quality Analyser performed well in a study at the Royal Surrey County Hospital in Guildford, UK, against WHO quality criteria. The study involved 50 measurements on a range of semen samples, including patients receiving chemotherapy, those who had undergone vasectomy and patients whose partners were undergoing intra-uterine insemination. Each sample was tested four times, with a mean SMI value taken. The SQA provides results in around 40 seconds, giving digital readings of the sperm motility index in three parameters: total concentration, percent motility and abnormal morphology.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.